yes you are right , Clinical trials should follow strict guidelines, Phase 1 trials typically focus on determining the safest dose, not the most effective dose. This is why CHECKVacc started with minimal CF33 dosages, despite these tiny doses, CHECKVacc has demonstrated enough antitumor activity in preclinical and initial human trials to justify progressing to VAXINIA with increased dosages.
After observing safety and initial efficacy with small doses in CHECKVacc, IMU has decided on staggered dosage increases in VAXINIA. This indicates they have/had strong confidence in CF33's ability to deliver results, even at higher doses.
Maybe this careful stepwise escalation in dosing is IMUs deliberate strategy to build in on CHECKVacc’s early success and refine to maximize CF33’s therapeutic impact.
IMU Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)